RecruitingPhase 3NCT06136559
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Sponsor: Merck Sharp & Dohme LLC
Florham Park, NJ · Hackensack, NJ · +47 more sites